Trulieve Welcomes Tikun Olam: A Partnership Rooted in Research

At Trulieve, we’re committed to bringing patients access to trusted brands that share our dedication to unmatched quality, continuous innovation, and service to patients. That’s why we’re excited to announce an exclusive new partnership with Tikun Olam, one of the most influential and research-driven names in cannabis worldwide, soon available exclusively at Trulieve. 

Global Cannabis Pioneers 

Tikun Olam has spent more than two decades pioneering patient-centered programs and expanding scientific understanding of cannabis through clinical research. Its body of evidence includes 7 clinical trials, 17 peer-reviewed studies¹, and more than 30,000 patient records.

Founded in Israel in 2005 as the one of the world’s first licensed medical cannabis provider, they’ve been able to advance cannabis research beyond the constraints of other nations’ prohibitive legal and regulatory landscapes, and develop proprietary genetics driven by those findings. Today, the company is recognized worldwide for its contributions to cannabis research and innovation. 

This partnership marks an exciting milestone, bringing strains and products from a globally respected cannabis pioneer to Florida patients. 

What Sets Tikun Olam Apart?

From the beginning, Tikun Olam has taken a unique approach to cannabis, combining cultivation expertise with an ongoing commitment to research and patient care. Over the years, they've built one of the largest collections of patient data in the industry, helping inform its understanding of consistency, genetics, and the patient experience.

Their work has contributed to a growing body of cannabis research and helped establish standards that continue to influence the industry today, including:

  • Award-winning proprietary Israeli strains backed by extensive clinical research.
  • One of the world’s largest treatment databases, with more than 30,000 unique patient records collected through direct care. 
  • Proprietary formulation and extraction methods ensuring consistent results. 
  • Avidekel, a high-CBD strain recognized as the first “highless marijuana” by Reuters². 
  • Nearly two decades of clinical research, including randomized controlled trials and large prospective real-world studies, on conditions such as cancer, inflammatory bowel disease, Parkinson's disease, Tourette syndrome, autism, and dementia, as well as one of the world's only studies evaluating cannabis and Crohn's disease.

Research That Shaped the Industry 

Professor Raphael Mechoulam's groundbreaking research helped lay the foundation for modern cannabis science. Often referred to as the “Godfather of Cannabis Research,” he is credited with discovering and isolating the THC molecule. His contributions transformed the understanding of cannabinoids and continue to shape cannabis research around the world. 

Mechoulam played an instrumental role in Tikun Olam’s earliest years as the PhD co-supervisor to Medical Director Dr. Lihi Bar-Lev Schleider, and as a co-author on four of Tikun Olam's original clinical research publications, including our studies in cancer, autism, older adults, and the large prospective general patient population study. His influence remains an important part of the Tikun Olam legacy and its ongoing commitment to advancing knowledge within the cannabis space. 

Tikun Olam’s research is guided by a dedicated medical advisory board of physicians and scientists including Dr. Adam Abodeely, Dr. Genester Wilson-King, Dr. Lihi Bar-Lev Schleider, Dr. Greg Gerdeman, and Dr. Mikhail Kogan, bringing clinical, surgical, and research expertise across specialties and reinforcing the company’s evidence-led approach to patient care. 

An International Leader Comes to Florida 

What began as a pioneering medical cannabis program in Israel has grown into an internationally recognized organization with a presence spanning North America and Europe. Throughout that growth, Tikun Olam has remained focused on the principles that helped define its early success: scientific curiosity, innovation, quality, and a commitment to putting patients first. 

Today, the company is known for its proprietary genetics, extensive research initiatives, and dedication to advancing the conversation around cannabis through education and discovery. That commitment to progress is one of many reasons this partnership feels like a natural fit. 

It’s a partnership built on a mutual belief that the future of cannabis innovation will be shaped by quality, education, and a deeper understanding of the plant. 

Putting Patients First, Now & Into the Future 

At Trulieve, we’ve always believed that patients deserve access to trusted products, reliable information, and brands that prioritize quality and consistency. Our partnership brings together two organizations that share a similar vision—helping patients feel confident in their cannabis journey while continuing to push the industry forward. 

We’re proud to welcome a partner whose impact on the cannabis industry has been felt around the world, and we are looking forward to revealing the lineup of exciting products coming soon to Florida. 

Sign up for text and email and stay tuned for updates about this exciting partnership. 

 

¹ Tikun Olam's research has been published in established peer-reviewed journals including the Journal of Crohn's and Colitis, Clinical Gastroenterology and Hepatology, Scientific Reports, Frontiers in Medicine, and the European Journal of Internal Medicine.
² Reuters, July 2012: Israeli Firm Grows First "Highless" Marijuana